Table 1.
In-vitro anticancer screening of compounds 2–21 against human breast cell line (MCF7).
Compound No. | IC50 (μg/mL) | IC50 (μM) |
---|---|---|
2 | 48.2 | 173.83 |
3 | 38.0 | 116.56 |
4 | 34.9 | 111.50 |
5 | 23.5 | 60.72 |
6 | 40.9 | 128.61 |
7 | 38.0 | 104.11 |
8 | 28.6 | 85.12 |
9 | 38.9 | 109.58 |
10 | 29.9 | 72.04 |
11 | NA | NA |
12 | 32.5 | 70.65 |
13 | 21.4 | 43.41 |
14 | 16.6 | 30.68 |
15 | NA | NA |
16 | 33.2 | 37.22 |
17 | 22.4 | 54.23 |
18 | 22.0 | 44.99 |
19 | 19.0 | 44.49 |
20 | 35.8 | 138.22 |
21 | NA | NA |
| ||
Doxorubicin | 39.0 | 71.8 |
NA: Compound having IC50 value > 100 μg/mL.